Please select the option that best describes you:
Topics:
Gastrointestinal Cancers • Medical Oncology
After neoadjuvant Nivolumab/Ipilimumab x4, do you offer adjuvant Nivolumab in the adjuvant setting for oligometastatic MSI-high colon cancer in a patient who achieved CR?
And if so for how long?